This partnership milestone de-risks Adagene's platform technology and provides a non-dilutive funding path for its masked CD3 T cell engager programs. Monitor for future milestone announcements and potential clinical data readouts from Third Arc Bio, as well as any updates on Adagene's lead program muzastotug (ADG126).
Price Chart
Executive Summary
Adagene announced that its partner Third Arc Bio selected the first lead candidate under their amended strategic collaboration for masked CD3 T cell engagers. The amended terms broaden the collaboration scope, with Third Arc Bio now sponsoring clinical development, and increase the total potential milestone payments to Adagene. Adagene retains a no-cost option to develop and commercialize in Greater China, Singapore, and South Korea, representing a modest positive de-risking event for its platform technology.
Key Facts
- Third Arc Bio selected the first lead candidate under the amended strategic licensing agreement for masked CD3 T cell engagers.
- Amended terms broaden the collaboration scope and increase total potential payments (development and commercial milestones) to Adagene.
- Third Arc Bio will sponsor and fund clinical development of the program.
- Adagene retains a no-cost option to develop and commercialize the candidate molecules in Greater China, Singapore and South Korea.
- The original agreement was established in November 2025.
Financial Impact
Total potential payments to Adagene (including development and commercial milestones) increased under the amended terms, but specific dollar amounts were not disclosed.
Risk Factors
- Milestone payments are contingent on future development and commercial success, which carry inherent clinical and regulatory risks.
- No specific financial terms were disclosed, making it difficult to quantify the near-term revenue impact.
- The collaboration is still early-stage; the lead candidate has not yet entered clinical trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-106554 |
| Document: tm2624950d1_6k.htm | 0001104659-26-106554 |
| Document: 0001104659-26-106554-index-headers.html | 0001104659-26-106554 |
| Document: 0001104659-26-106554-index.html | 0001104659-26-106554 |
| Document: 0001104659-26-106554.txt | 0001104659-26-106554 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $3.20 | awaiting T+60 | — | $2.49 (−22.19%) |
Sep 22, 2026 4w ago | 6-K | $3.23 | awaiting T+60 | — | $2.49 (−22.91%) |
Sep 10, 2026 6w ago | 6-K | $3.31 | awaiting T+60 | — | $2.49 (−24.77%) |
Sep 9, 2026 6w ago | 6-K | $3.27 | awaiting T+60 | — | $2.49 (−23.85%) |
Aug 16, 2026 10w ago | Institutional Cluster | $3.83 | awaiting T+60 | — | $2.49 (−34.99%) |
Aug 12, 2026 10w ago | 6-K | $3.75 | awaiting T+60 | — | $2.49 (−33.60%) |
Aug 12, 2026 10w ago | Press Release | $3.75 | awaiting T+60 | — | $2.49 (−33.60%) |
Jul 6, 2026 16w ago | 6-K | $3.93 $3.21 | ▼ −18.32% | ▼ −20.04% | $2.49 (−36.64%) |
Apr 17, 2026 27w ago | 6-K | $3.89 $3.67 | ▼ −5.66% | ▼ −12.43% | $2.49 (−35.99%) |
Apr 2, 2026 29w ago | 6-K | $3.99 $4.20 | ▼ −5.26% | ▲ +8.90% | $2.49 (+37.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers